PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Abstract

In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.).